181 related articles for article (PubMed ID: 36484549)
1. Drug repurposing for cardiovascular diseases: New targets and indications for probenecid.
Onódi Z; Koch S; Rubinstein J; Ferdinandy P; Varga ZV
Br J Pharmacol; 2023 Mar; 180(6):685-700. PubMed ID: 36484549
[TBL] [Abstract][Full Text] [Related]
2. Repurposing drugs targeting the P2X7 receptor to limit hyperinflammation and disease during influenza virus infection.
Rosli S; Kirby FJ; Lawlor KE; Rainczuk K; Drummond GR; Mansell A; Tate MD
Br J Pharmacol; 2019 Oct; 176(19):3834-3844. PubMed ID: 31271646
[TBL] [Abstract][Full Text] [Related]
3. Repositioning of drugs using open-access data portal DTome: A test case with probenecid (Review).
Ahmed MU; Bennett DJ; Hsieh TC; Doonan BB; Ahmed S; Wu JM
Int J Mol Med; 2016 Jan; 37(1):3-10. PubMed ID: 26572802
[TBL] [Abstract][Full Text] [Related]
4. Probenecid, an Old Drug with Potential New Uses for Central Nervous System Disorders and Neuroinflammation.
García-Rodríguez C; Mujica P; Illanes-González J; López A; Vargas C; Sáez JC; González-Jamett A; Ardiles ÁO
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371611
[TBL] [Abstract][Full Text] [Related]
5. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation.
Koch SE; Gao X; Haar L; Jiang M; Lasko VM; Robbins N; Cai W; Brokamp C; Varma P; Tranter M; Liu Y; Ren X; Lorenz JN; Wang HS; Jones WK; Rubinstein J
J Mol Cell Cardiol; 2012 Jul; 53(1):134-44. PubMed ID: 22561103
[TBL] [Abstract][Full Text] [Related]
6. Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?
Tunstall BJ; Lorrai I; McConnell SA; Gazo KL; Zallar LJ; de Guglielmo G; Hoang I; Haass-Koffler CL; Repunte-Canonigo V; Koob GF; Vendruscolo LF; Sanna PP
Alcohol Alcohol; 2019 Jan; 54(5):497-502. PubMed ID: 31535696
[TBL] [Abstract][Full Text] [Related]
7. Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model.
Koch SE; Tranter M; Robbins N; Luther K; Singh U; Jiang M; Ren X; Tee T; Smith L; Varma P; Jones WK; Rubinstein J
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):280-9. PubMed ID: 23241275
[TBL] [Abstract][Full Text] [Related]
8. Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
Onusko E; McDermott MR; Robbins N; Liu G; Kranias EG; Rubinstein J; Koch SE
PLoS One; 2020; 15(3):e0230386. PubMed ID: 32218573
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?
Gelosa P; Castiglioni L; Camera M; Sironi L
Biochem Pharmacol; 2020 Jul; 177():113894. PubMed ID: 32142728
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout.
Kim SC; Neogi T; Kang EH; Liu J; Desai RJ; Zhang M; Solomon DH
J Am Coll Cardiol; 2018 Mar; 71(9):994-1004. PubMed ID: 29496000
[TBL] [Abstract][Full Text] [Related]
11. Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.
Robbins N; Gilbert M; Kumar M; McNamara JW; Daly P; Koch SE; Conway G; Effat M; Woo JG; Sadayappan S; Rubinstein J
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29331959
[TBL] [Abstract][Full Text] [Related]
12. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
13. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure.
Korkmaz-Icöz S; Radovits T; Szabó G
Br J Pharmacol; 2018 Jan; 175(2):223-231. PubMed ID: 28213937
[TBL] [Abstract][Full Text] [Related]
14. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
15. Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease.
Robbins N; Koch SE; Rubinstein J
Transl Res; 2013 Jun; 161(6):469-76. PubMed ID: 23453732
[TBL] [Abstract][Full Text] [Related]
16. Novel role of transient receptor potential vanilloid 2 in the regulation of cardiac performance.
Rubinstein J; Lasko VM; Koch SE; Singh VP; Carreira V; Robbins N; Patel AR; Jiang M; Bidwell P; Kranias EG; Jones WK; Lorenz JN
Am J Physiol Heart Circ Physiol; 2014 Feb; 306(4):H574-84. PubMed ID: 24322617
[TBL] [Abstract][Full Text] [Related]
17. Repurposing drugs to treat cardiovascular disease in the era of precision medicine.
Abdelsayed M; Kort EJ; Jovinge S; Mercola M
Nat Rev Cardiol; 2022 Nov; 19(11):751-764. PubMed ID: 35606425
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of approved cardiovascular drugs.
Ishida J; Konishi M; Ebner N; Springer J
J Transl Med; 2016 Sep; 14():269. PubMed ID: 27646033
[TBL] [Abstract][Full Text] [Related]
19. Probenecid, a gout remedy, inhibits pannexin 1 channels.
Silverman W; Locovei S; Dahl G
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C761-7. PubMed ID: 18596212
[TBL] [Abstract][Full Text] [Related]
20. Probenecid induces the recovery of renal ischemia/reperfusion injury via the blockade of Pannexin 1/P2X7 receptor axis.
El-Maadawy WH; Hassan M; Badawy MH; AbuSeada A; Hafiz E
Life Sci; 2022 Nov; 308():120933. PubMed ID: 36075473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
